Inozyme Pharma Inc (INZY) - Net Assets
Based on the latest financial reports, Inozyme Pharma Inc (INZY) has net assets worth $31.80 Million USD as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($95.16 Million) and total liabilities ($63.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Inozyme Pharma Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $31.80 Million |
| % of Total Assets | 33.41% |
| Annual Growth Rate | N/A |
| 5-Year Change | -63.43% |
| 10-Year Change | N/A |
| Growth Volatility | 31.02 |
Inozyme Pharma Inc - Net Assets Trend (2018–2024)
This chart illustrates how Inozyme Pharma Inc's net assets have evolved over time, based on quarterly financial data. Also explore INZY total asset value for the complete picture of this company's asset base.
Annual Net Assets for Inozyme Pharma Inc (2018–2024)
The table below shows the annual net assets of Inozyme Pharma Inc from 2018 to 2024. For live valuation and market cap data, see Inozyme Pharma Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $57.83 Million | -58.84% |
| 2023-12-31 | $140.48 Million | +18.65% |
| 2022-12-31 | $118.39 Million | +8.35% |
| 2021-12-31 | $109.27 Million | -30.89% |
| 2020-12-31 | $158.10 Million | +575.94% |
| 2019-12-31 | $-33.22 Million | -139.42% |
| 2018-12-31 | $-13.88 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Inozyme Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 37302600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.01% |
| Other Comprehensive Income | $69.00K | 0.12% |
| Other Components | $445.70 Million | 770.77% |
| Total Equity | $57.83 Million | 100.00% |
Inozyme Pharma Inc Competitors by Market Cap
The table below lists competitors of Inozyme Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
UTKARSH SMALL FINANCE BANK ORD (BSE)
NSE:UTKARSHBNK
|
$258.27 Million |
|
Pioneer Acquisition I Corp Class A Ordinary Shares
NASDAQ:PACH
|
$258.31 Million |
|
Namhae Chemical
KO:025860
|
$258.33 Million |
|
Sarawak Plantation Bhd
KLSE:5135
|
$258.51 Million |
|
Pointsbet Holdings Ltd
AU:PBH
|
$258.24 Million |
|
PLINTAS
KLSE:5320
|
$258.22 Million |
|
NeXGold Mining Corp
V:NEXG
|
$258.21 Million |
|
Hot Chili Ltd
AU:HCH
|
$258.21 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Inozyme Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 140,479,000 to 57,826,000, a change of -82,653,000 (-58.8%).
- Net loss of 102,024,000 reduced equity.
- Share repurchases of 281,000 reduced equity.
- New share issuances of 10,521,000 increased equity.
- Other comprehensive income increased equity by 28,000.
- Other factors increased equity by 9,103,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-102.02 Million | -176.43% |
| Share Repurchases | $281.00K | -0.49% |
| Share Issuances | $10.52 Million | +18.19% |
| Other Comprehensive Income | $28.00K | +0.05% |
| Other Changes | $9.10 Million | +15.74% |
| Total Change | $- | -58.84% |
Book Value vs Market Value Analysis
This analysis compares Inozyme Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.34x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-0.92 | $4.00 | x |
| 2019-12-31 | $-2.19 | $4.00 | x |
| 2020-12-31 | $6.76 | $4.00 | x |
| 2021-12-31 | $4.64 | $4.00 | x |
| 2022-12-31 | $3.14 | $4.00 | x |
| 2023-12-31 | $2.71 | $4.00 | x |
| 2024-12-31 | $0.92 | $4.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Inozyme Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -176.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.13x
- Recent ROE (-176.43%) is below the historical average (-52.75%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.58 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.30 Million |
| 2020 | -35.32% | 0.00% | 0.00x | 1.07x | $-71.65 Million |
| 2021 | -51.63% | 0.00% | 0.00x | 1.13x | $-67.34 Million |
| 2022 | -55.19% | 0.00% | 0.00x | 1.17x | $-77.31 Million |
| 2023 | -50.66% | 0.00% | 0.00x | 1.43x | $-85.22 Million |
| 2024 | -176.43% | 0.00% | 0.00x | 2.13x | $-107.81 Million |
Industry Comparison
This section compares Inozyme Pharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $173,871,658
- Average return on equity (ROE) among peers: -26.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Inozyme Pharma Inc (INZY) | $31.80 Million | 0.00% | 1.99x | $258.25 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $98.85 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $1.59 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $309.44 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $181.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $795.12 Million |
| Arbutus Biopharma Corp (ABUS) | $200.23 Million | -28.52% | 0.14x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $-5.75 Million | 0.00% | 0.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.67 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $52.99 Million | -121.23% | 0.22x | $3.61 Billion |
About Inozyme Pharma Inc
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney… Read more